PBH News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PB

Mkt Cap

$2.36B

Volume

478.65K

Next Earnings

November 5th

Loading chart

PB

PBHPrestige Consumer Healthcare Inc.

PBH

Pay with—

Available Balance0.00

PB

Mkt Cap

$2.36B

Volume

478.65K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average.Zacks Investment Research · Oct 15, 2026

Best Value Stocks to Buy for October 1stRecent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. The market is now focused on the upcoming Friday employment report. Two stocks highlighted as strong buys are BP, an integrated energy company with a Zacks Rank #1 and improving earnings estimates, and Prestige Consumer Healthcare, also with a Zacks Rank #1 rating.Zacks Investment Research · Oct 1, 2026

PBH vs. NEOG: Which Stock Is the Better Value Option?A comparison of two Medical-Products stocks reveals that Prestige Consumer Healthcare (PBH) offers superior value compared to Neogen (NEOG). While both companies share a Zacks Rank #2 (Buy) rating with improving earnings outlooks, PBH demonstrates significantly better valuation metrics with a forward P/E of 10.26 versus NEOG's 41.51, a PEG ratio of 1.47 versus 4.15, and a Value grade of A versus D.Zacks Investment Research · Sep 30, 2026

Is This the Right Time to Add PBH Stock to Your Portfolio?Prestige Consumer Healthcare (PBH) is a Zacks Rank #2 (Buy) stock benefiting from strategic acquisitions of Breathe Right and LaCorium Health, expected to add nearly 20% to its revenue base and lift fiscal 2027 guidance to $1.29-$1.315 billion. The company's e-commerce channel has grown to 18% of net sales with double-digit growth momentum. However, elevated debt levels ($2.0 billion net debt) and foreign exchange exposure pose risks to profitability.Zacks Investment Research · Sep 2, 2026

Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results DatePrestige Consumer Healthcare completed its acquisition of LaCorium Health for approximately $150 million on July 1, 2026. The company also priced a $400 million offering of 6.25% senior notes due 2034, with proceeds intended to redeem $400 million of existing 5.125% senior notes due January 2028. LaCorium, an Australian therapeutic skincare company generating ~$40 million in annual revenue, is expected to contribute approximately $12 million in EBITDA post-integration.GlobeNewswire Inc. · Jul 6, 2026

Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.While Alphabet's addition to the Dow and prominence in Berkshire Hathaway's portfolio has garnered significant attention, Prestige Consumer Healthcare may offer better investment potential. Prestige completed its largest acquisition, purchasing Breathe Right and other OTC brands for $1.045 billion, expanding its portfolio of category-leading brands. The company is also positioning itself to benefit from GLP-1 weight-loss medication side effects through its existing brands like Dramamine and Fleet. However, the acquisition has elevated debt to 4.0x EBITDA, requiring successful execution to reduce leverage by 2028.The Motley Fool · Jul 3, 2026

Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, Hagens Berman InvestigatingPrestige Consumer Healthcare (PBH) shares dropped over 11% on May 14, 2026, after the company reported significant revenue declines and production problems at its recently acquired Pillar5 facility. The facility, which was supposed to resolve Clear Eyes supply chain constraints, failed to deliver expected results. Q4 2026 revenues fell 5% year-over-year, with North America OTC Eye & Ear Care declining 20.6%. Hagens Berman has opened an investigation into whether the company adequately disclosed these issues to investors.GlobeNewswire Inc. · Jun 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBHPomerantz LLP is investigating potential securities fraud claims against Prestige Consumer Healthcare Inc. following the company's May 13, 2026 earnings announcement that revealed a 4.5% organic revenue decline and production issues with Clear Eyes products. The stock fell 11.35% to $45.93 per share on May 14, 2026, prompting the investigation into whether company officers and directors engaged in unlawful business practices.GlobeNewswire Inc. · Jun 9, 2026

National Advertising Division Finds Certain Eosera Ear Wax MD Claims Supported; Recommends Others Be Modified or DiscontinuedThe National Advertising Division reviewed advertising claims for eosera Inc.'s Ear Wax MD product in a challenge brought by Prestige Consumer Healthcare Inc. (marketer of Debrox). NAD found some establishment and mechanism-of-action claims were supported, but recommended discontinuing or modifying comparative superiority claims and unqualified effectiveness claims that overstated results. eosera agreed to comply with NAD's recommendations.GlobeNewswire Inc. · Apr 23, 2026

Prestige Bets $1 Billion On World's Most Iconic Nasal StripPrestige Consumer Healthcare announced a definitive agreement to acquire the Breathe Right brand for $1.045 billion. The acquisition will expand Prestige's consumer health portfolio in sleep and breathing categories and includes other brands like Dimetapp. The deal is expected to close in H1 fiscal 2027 and should boost margins and free cash flow. However, the stock shows technical weakness, trading below its moving averages with negative MACD signals.Benzinga · Mar 20, 2026

to start trading

PB

PBHPrestige Consumer Healthcare Inc.

PBH

Pay with—

Available Balance0.00

Your PositionYou don't own any PBH yet.

Related Tickers

Earnings